Table 3: Phase-I-II-III studies with pegylated liposomal doxorubicin (PLD) in combination with target agents.

AuthorDose/scheduleClinical setting
PFI (mts)
No. ptsRR (%)PFS (median)
(mts)

Muggia et al. [55]PLD 30 mg/m and
BEV 15 mg/kg on cycles 2–7 (with option to continue)
≤648OngoingOngoing

Pujade-Lauraine et al. [56]Arm1
PTX (80 mg/m2) d1, 8, 15 and 22 q28
or
TPT (4 mg/m2) d1, 8, 15 q28
or
PLD (40 mg/m2) d1 q28
≤6 166 12.6 3.4
Arm2
BEV 10 m/kg d1 q15 or 15 mg/kg d1 q21,
PTX (80 mg/m2) d1, 8, 15 and 22 q28
or
TPT (4 mg/m2) d1, 8, 15 q28
or
PLD (40 mg/m2) d1 q28
13530.96.7

Del Carmen et al. [57] PLD (30 mg/m2) d1 q28,
CBDCA (AUC5) d1 q28, Beva 10 mg/kg d1 q14
≥65472.213.9

Steffensen et al. [58] PAN 6 mg/kg d1, 15 q28/PLD 40 mg/m² day 1 q28≤64624.32.7–8.1

TRINOVA 2 [59] http://clinicaltrials.gov/show/NCT01281254Arm 1
PLD 50 mg/m² d1 q28 and blinded AMG 386 15 mg/kg qw
Arm 2
PLD 50 mg/m² d1 q28 and blinded AMG 386/placebo qw
≤12Ongoing Ongoing Ongoing

Boers-Sonderen et al. [60] T 15–20 mg/m²/PLD 20–40 mg/mqALL
20
3PR
9SD
4.9

PFS: progression-free survival; PTX: paclitaxel; TPT: topotecan; T: temsirolimus; PAN: panitumumab; BEV: bevacizumab; RR: response rate; SEN: platinum-sensitive recurrentdisease; TRAB: trabectedin; q: every; d: day. *Statistically significant.